Literature DB >> 25404244

p53 in liver pathologies-taking the good with the bad.

Meital Charni1, Noa Rivlin, Alina Molchadsky, Ronit Aloni-Grinstein, Varda Rotter.   

Abstract

The distinct physiology of the liver makes it a unique ground with respect to its cross talk with p53, the "guardian of the genome." The stressful environment in the liver frequently leads to the activation of p53, which is associated with alterations in metabolic pathways and induction of apoptosis. The latter serves as a mechanism that controls the deposal of DNA-damaged cells. However, accentuated apoptosis may eventually lead to liver pathologies, mainly steatosis, which can develop into a more severe disease such as steatohepatitis, fibrosis, and cirrhosis. These pathologies, together with other apoptosis outcome such as chronic inflammation, may pave the way toward cancer development. In addition to this unique scenario that connects the ongoing response of wild-type (WT) p53 to stress and cancer development, hepatocarcinoma may develop in other well-described mechanisms involving p53. One such example is hepatitis virus-induced liver cancer whereby p53 is inactivated upon the binding of a specific viral protein, leading to the loss of its tumor suppressive activity. Furthermore, the accumulations of carcinogens such as aflatoxin were shown to yield an oncogenic mutated p53 protein. In this review, we will demonstrate the diverse activities of p53 in the liver. Interestingly, some of these activities may protect the liver from cancer in the short term, yet in the long term, p53 may lead to malignant transformation. A better understanding of the complex clinical outcome of p53 function in the liver may shed light on future therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25404244     DOI: 10.1007/s00109-014-1223-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  52 in total

1.  p53/p66Shc-mediated signaling contributes to the progression of non-alcoholic steatohepatitis in humans and mice.

Authors:  Kengo Tomita; Toshiaki Teratani; Takahiro Suzuki; Tetsuya Oshikawa; Hirokazu Yokoyama; Katsuyoshi Shimamura; Kiyoshi Nishiyama; Norikazu Mataki; Rie Irie; Tohru Minamino; Yoshikiyo Okada; Chie Kurihara; Hirotoshi Ebinuma; Hidetsugu Saito; Ippei Shimizu; Yohko Yoshida; Ryota Hokari; Kazuo Sugiyama; Kazuo Hatsuse; Junji Yamamoto; Takanori Kanai; Soichiro Miura; Toshifumi Hibi
Journal:  J Hepatol       Date:  2012-05-26       Impact factor: 25.083

2.  Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.

Authors:  Hyun Goo Woo; Xin Wei Wang; Anuradha Budhu; Yun Hee Kim; So Mee Kwon; Zhao-You Tang; Zongtang Sun; Curtis C Harris; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2010-11-19       Impact factor: 22.682

Review 3.  Regulation of lipid metabolism by p53 - fighting two villains with one sword.

Authors:  Ido Goldstein; Varda Rotter
Journal:  Trends Endocrinol Metab       Date:  2012-07-20       Impact factor: 12.015

4.  p53: the barrier to cancer stem cell formation.

Authors:  Ronit Aloni-Grinstein; Yoav Shetzer; Tom Kaufman; Varda Rotter
Journal:  FEBS Lett       Date:  2014-02-19       Impact factor: 4.124

Review 5.  Sirtuins as regulators of metabolism and healthspan.

Authors:  Riekelt H Houtkooper; Eija Pirinen; Johan Auwerx
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-07       Impact factor: 94.444

6.  Geographic variation of p53 mutational profile in nonmalignant human liver.

Authors:  F Aguilar; C C Harris; T Sun; M Hollstein; P Cerutti
Journal:  Science       Date:  1994-05-27       Impact factor: 47.728

7.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

Review 8.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Authors:  György Baffy; Elizabeth M Brunt; Stephen H Caldwell
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

9.  p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver.

Authors:  Svitlana Kurinna; Sabrina A Stratton; Zeynep Coban; Jill M Schumacher; Markus Grompe; Andrew W Duncan; Michelle Craig Barton
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

Review 10.  Multiple interactive factors in hepatocarcinogenesis.

Authors:  Jin Ding; Hongyang Wang
Journal:  Cancer Lett       Date:  2013-12-25       Impact factor: 8.679

View more
  8 in total

Review 1.  Regulation of hepatocyte identity and quiescence.

Authors:  Carmen Berasain; Matías A Avila
Journal:  Cell Mol Life Sci       Date:  2015-06-19       Impact factor: 9.261

2.  The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation.

Authors:  Yael Aylon; Anat Gershoni; Ron Rotkopf; Inbal E Biton; Ziv Porat; Anna P Koh; Xiaochen Sun; Youngmin Lee; Maria-Isabel Fiel; Yujin Hoshida; Scott L Friedman; Randy L Johnson; Moshe Oren
Journal:  Genes Dev       Date:  2016-03-24       Impact factor: 11.361

3.  Systematic revelation of the protective effect and mechanism of Cordycep sinensis on diethylnitrosamine-induced rat hepatocellular carcinoma with proteomics.

Authors:  Pei-Wen Wang; Yu-Chiang Hung; Wen-Tai Li; Chau-Ting Yeh; Tai-Long Pan
Journal:  Oncotarget       Date:  2016-09-13

Review 4.  p53 on the crossroad between regeneration and cancer.

Authors:  Meital Charni; Ronit Aloni-Grinstein; Alina Molchadsky; Varda Rotter
Journal:  Cell Death Differ       Date:  2016-10-21       Impact factor: 15.828

5.  Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner.

Authors:  Meital Charni-Natan; Hilla Solomon; Alina Molchadsky; Adi Jacob-Berger; Naomi Goldfinger; Varda Rotter
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

Review 6.  Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.

Authors:  Yan Stein; Varda Rotter; Ronit Aloni-Grinstein
Journal:  Int J Mol Sci       Date:  2019-12-08       Impact factor: 5.923

Review 7.  TC2N: A Novel Vital Oncogene or Tumor Suppressor Gene In Cancers.

Authors:  Hanyang Li; He Fang; Li Chang; Shuang Qiu; Xiaojun Ren; Lidong Cao; Jinda Bian; Zhenxiao Wang; Yi Guo; Jiayin Lv; Zhihui Sun; Tiejun Wang; Bingjin Li
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

Review 8.  p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine.

Authors:  Jelena Krstic; Markus Galhuber; Tim J Schulz; Michael Schupp; Andreas Prokesch
Journal:  Int J Mol Sci       Date:  2018-03-20       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.